Cutaneous involvement of dermatomyositis can respond to Dapsone therapy

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Dapsone (4,4-diaminodiphenylsulfone) is a sulfone antibiotic used in the treatment of leprosy, but dermatologists more commonly utilize its anti-inflammatory properties particularly directed against leukocytes to treat various bullous disorders, erythema nodosum, pyoderma gangrenosum, Sweet's syndrome, cutaneous vasculitis, and cutaneous forms of lupus erythematosus. The cutaneous manifestations of dermatomyositis are often resistant to antimalarial and immunosuppressive therapies. Methods: Two patients with cutaneous dermatomyositis unresponsive to combination therapy with prednisone, hydroxychloroquine, quinacrine, and immunosuppressive medications had Dapsone added to their therapy. Results: Both patients showed rapid improvement with the addition of Dapsone. Each had an exacerbation of their cutaneous dermatomyositis on Dapsone with withdrawal and subsequent improvement when the Dapsone was reinstituted. Conclusions: Dapsone therapy for cutaneous dermatomyositis may have a wider role inc treatment for these patients refractory to prednisone and antimalarial therapy.

Original languageEnglish (US)
Pages (from-to)182-184
Number of pages3
JournalInternational Journal of Dermatology
Volume41
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Dapsone
Dermatomyositis
Skin
Antimalarials
Immunosuppressive Agents
Prednisone
Therapeutics
Cutaneous Lupus Erythematosus
Sweet Syndrome
Hydroxychloroquine
Pyoderma Gangrenosum
Skin Manifestations
Erythema Nodosum
Quinacrine
Sulfones
Leprosy
Vasculitis
Leukocytes
Anti-Inflammatory Agents
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Dermatology

Cite this

Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. / Cohen, Jack B.

In: International Journal of Dermatology, Vol. 41, No. 3, 2002, p. 182-184.

Research output: Contribution to journalArticle

@article{ca7059928d4541ebbf31e4f47d04726e,
title = "Cutaneous involvement of dermatomyositis can respond to Dapsone therapy",
abstract = "Background: Dapsone (4,4-diaminodiphenylsulfone) is a sulfone antibiotic used in the treatment of leprosy, but dermatologists more commonly utilize its anti-inflammatory properties particularly directed against leukocytes to treat various bullous disorders, erythema nodosum, pyoderma gangrenosum, Sweet's syndrome, cutaneous vasculitis, and cutaneous forms of lupus erythematosus. The cutaneous manifestations of dermatomyositis are often resistant to antimalarial and immunosuppressive therapies. Methods: Two patients with cutaneous dermatomyositis unresponsive to combination therapy with prednisone, hydroxychloroquine, quinacrine, and immunosuppressive medications had Dapsone added to their therapy. Results: Both patients showed rapid improvement with the addition of Dapsone. Each had an exacerbation of their cutaneous dermatomyositis on Dapsone with withdrawal and subsequent improvement when the Dapsone was reinstituted. Conclusions: Dapsone therapy for cutaneous dermatomyositis may have a wider role inc treatment for these patients refractory to prednisone and antimalarial therapy.",
author = "Cohen, {Jack B.}",
year = "2002",
doi = "10.1046/j.1365-4362.2002.01409.x",
language = "English (US)",
volume = "41",
pages = "182--184",
journal = "International Journal of Dermatology",
issn = "0011-9059",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Cutaneous involvement of dermatomyositis can respond to Dapsone therapy

AU - Cohen, Jack B.

PY - 2002

Y1 - 2002

N2 - Background: Dapsone (4,4-diaminodiphenylsulfone) is a sulfone antibiotic used in the treatment of leprosy, but dermatologists more commonly utilize its anti-inflammatory properties particularly directed against leukocytes to treat various bullous disorders, erythema nodosum, pyoderma gangrenosum, Sweet's syndrome, cutaneous vasculitis, and cutaneous forms of lupus erythematosus. The cutaneous manifestations of dermatomyositis are often resistant to antimalarial and immunosuppressive therapies. Methods: Two patients with cutaneous dermatomyositis unresponsive to combination therapy with prednisone, hydroxychloroquine, quinacrine, and immunosuppressive medications had Dapsone added to their therapy. Results: Both patients showed rapid improvement with the addition of Dapsone. Each had an exacerbation of their cutaneous dermatomyositis on Dapsone with withdrawal and subsequent improvement when the Dapsone was reinstituted. Conclusions: Dapsone therapy for cutaneous dermatomyositis may have a wider role inc treatment for these patients refractory to prednisone and antimalarial therapy.

AB - Background: Dapsone (4,4-diaminodiphenylsulfone) is a sulfone antibiotic used in the treatment of leprosy, but dermatologists more commonly utilize its anti-inflammatory properties particularly directed against leukocytes to treat various bullous disorders, erythema nodosum, pyoderma gangrenosum, Sweet's syndrome, cutaneous vasculitis, and cutaneous forms of lupus erythematosus. The cutaneous manifestations of dermatomyositis are often resistant to antimalarial and immunosuppressive therapies. Methods: Two patients with cutaneous dermatomyositis unresponsive to combination therapy with prednisone, hydroxychloroquine, quinacrine, and immunosuppressive medications had Dapsone added to their therapy. Results: Both patients showed rapid improvement with the addition of Dapsone. Each had an exacerbation of their cutaneous dermatomyositis on Dapsone with withdrawal and subsequent improvement when the Dapsone was reinstituted. Conclusions: Dapsone therapy for cutaneous dermatomyositis may have a wider role inc treatment for these patients refractory to prednisone and antimalarial therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036267607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036267607&partnerID=8YFLogxK

U2 - 10.1046/j.1365-4362.2002.01409.x

DO - 10.1046/j.1365-4362.2002.01409.x

M3 - Article

C2 - 12010348

AN - SCOPUS:0036267607

VL - 41

SP - 182

EP - 184

JO - International Journal of Dermatology

JF - International Journal of Dermatology

SN - 0011-9059

IS - 3

ER -